---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-040276"
form_type: "8-K"
ticker: "QCLS"
cik: "0001321834"
company_name: "Q/C TECHNOLOGIES, INC."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:05:05.458502+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# TNF Pharma raises $600k via private placement at 20% premium; CRO partner engaged

## Summary
- Sold 283,019 shares at $2.12/share (120% of 30-day VWAP) to Prevail Partners, gross proceeds $600k.
- Proceeds for working capital; may be used to pay Prevail InfoWorks invoices under an August 2024 services agreement.
- Prevail InfoWorks engaged as CRO for upcoming Phase 2 sarcopenia/frailty study of MYMD-1 TNFα inhibitor.
- Press release states company is fully funded for clinical trials for next two years.
- MYMD-1 previously met primary endpoints in a small Phase 2 sarcopenia study (2023) reducing chronic inflammatory markers.

## SEC filing metadata
- accession: 0001493152-24-040276
- form_type: 8-K
- ticker: QCLS
- cik: 0001321834
- company_name: Q/C TECHNOLOGIES, INC.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 3.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1321834/000149315224040276/0001493152-24-040276-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1321834/000149315224040276/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-040276
- JSON: https://secwatch.observer/filing/0001493152-24-040276.json
- Plain text: https://secwatch.observer/filing/0001493152-24-040276.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.